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Abstract
Background: Mast cells have been documented to have several key functions with regards to
malignant neoplasms. However, the functional significance of their accumulation is largely unknown.
An analysis of the mast cell profile in mediastinal lymph nodes from lung cancer patients is reported
here.
Methods: One hundred thirty-four, randomly selected lymph nodes (63 with positive pathological
lymph node status) from 39 surgically treated lung cancer patients were examined. All cancer
negative nodes were obtained from stage I patients. Mast cells were stained with Alcian blue and
safranin O. Metastatic cancer cells were stained using anti-cytokeratin antibody.
Results:  Immunohistochemical studies with cytokeratin revealed micro metastasis in 9/71
(12.68%) nodes previously diagnosed as histological negative. In tumor-free mediastinal lymph
nodes, the mast cell count was significantly higher than in metastatic nodes. In all cases, mast cells
were observed primarily in the T-cell area.
Conclusions: An inverse relationship was observed between the number of mast cells and the
amount of tumor tissue. The presence of mast cells primarily in the T-cell area implies a relationship
between mast cells and the T-cell system. From the present study it is not possible to conclude
whether mast cells in lymph nodes are for or against tumor spread.
Introduction
Numerous studies on mast cells have revealed its several
key functions with regard to malignant disease process
[1]. These include anti tumor functions of natural cytotox-
icity [2,3], and release of anti tumor compounds [4,5],
while on the other it has also been associated with angio-
neogenesis [6–9]. The functional significance of accumu-
lation of mast cells around tumor is a subject of
controversy because of contradictory previous experimen-
tal data [10]. It is still not clear whether mast cells are for
or against tumor spread [10], however, a correlation
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between mast cells and survival in pulmonary adenocarci-
noma has been previously demonstrated [11].
Little attention has been paid to the role of mast cells in
lymph nodes from patients with malignant neoplasms.
Several of these have produced contradictory results with
some reporting an increased number of mast cells [12–
14], while others reported no change or even a decrease in
their number [15,16]. The present study analyzes the mast
cell profile in mediastinal lymph nodes from lung cancer
patients.
Materials and methods
Randomly 134 formalin-fixed and paraffin-embedded
lymph nodes from 39 primary lung cancer patients (24
adenocarcinoma and 15 squamous cell carcinoma)
treated surgically at Miyazaki Medical College during
1994–1995 were selected. Of these, 15 patients were in
stage I, 2 in stage II, 13 in stage IIIA, and 2 in stage IIIB.
None of the patient was a smoker. Routine pathological
examination with hematoxylin and eosin staining
revealed 63 nodes to be metastasis positive. All cancer
negative nodes were obtained from stage I patients. Using
one paraffin block for each node, studies were conducted
to determine the number of mast cells and to detect the
presence of cytokeratin positivity.
Serialized 4 µm-thick sections were deparaffinized, rehy-
drated, and stained with Alcian blue (pH 0.3) and
safranin O (pH 0.1). The number of mast cell per 5 fields
at a magnification of 200× was counted under light micro-
scopy. These results were assessed semi quantitatively by
two authors, and the average count was used as the final
score.
The specific monoclonal antibody against cytokeratin 19
(Santa Cruz Biotechnology, California, U.S.A.) was used
to detect micro metastasis. Before staining, serialized
4µm-thick sections were deparaffinized in three changes
of lemosol and rehydrated through a descending series of
ethanol. These sections were immersed in 0.6% H2O2 in
methanol for 20 minutes at room temperature to block
endogenous peroxidase activity. After blocking non-spe-
cific protein bindings by incubating with Block Ace®
(Dainippon Inc., Osaka, Japan), the sections were incu-
bated overnight at 4°C with primary antibodies against
human cytokeratin (1:50). Subsequently, sections were
incubated with secondary antiserum (1:500) for one
hour, followed by incubation with peroxidase anti-perox-
idase complexes for 30 minute at room temperature. The
sections were visualized with the diaminobenzidine/
metal concentration (10x) and stable peroxide substrate
buffer (1x) system (Pierce, Rockford, Illinois, U.S.A.).
After washing with water, they were counterstained with
hematoxylin. Double staining for mast cells and cytokera-
tin was also performed to determine the correlation
between mast cells and metastasis. Sections were stained
with cytokeratin antibody in the same manner as
described above the were counter stained with Alcian blue
and safranin O. Immunohistochemical results too were
assessed semi quantitatively by two authors.
Data was analyzed using the Student's t-test and the
Mann-Whitney U test. Differences were considered signif-
icant when the p value was less than 0.05.
Results
Immunohistochemical staining with cytokeratin revealed
micro metastasis in 9/71 (12.68%) nodes that were previ-
ously diagnosed as histologically negative. In the 63
metastasis-positive nodes, all samples showed positive
staining with cytokeratin. Based on these results, samples
were divided into three groups: group A, metastasis nega-
tive by both routine pathological study and cytokeratin
staining; group B, micro metastasis (malignant cells nega-
tive by pathological study, but positive by cytokeratin
staining); and group C, metastasis positive by both
techniques.
Mast cells were observed in the subcapsular sinus, para-
cortical areas, medullary cords, and medullary sinus (Fig-
ure 1) and were rarely seen in the B cell area. The mast cell
count in tumor-free mediastinal lymph nodes (33.23 ±
24.58) of lung cancer patients was significantly higher
than in lymph nodes showing metastasis (19.78 ± 12.76,
and 9.69 ± 9.37 in group B and C respectively; group A vs.
B: P = 0.0155; group B vs. C: P = 0.0064; group A vs. C: P
= 0.0019). Metastatic lymph nodes had very few mast
cells. This trend was observed in patients with both aden-
ocarcinoma and squamous cell carcinoma. However the
groups are too small to have meaningful separation.
In cancer-positive nodes, mast cells were observed prima-
rily around tumor deposits with an occasional mast cell
seen within the metastatic foci.
Discussion
It is not clear till date, whether mast cells are for or against
the tumor growth [10]. The functional significance of
accumulation of mast cells around tumor areas is a subject
of controversy because of contradictory previous experi-
mental data [10]. The results of the present study demon-
strate significant differences in the number of mast cells
among group A and C in mediastinal lymph nodes. How-
ever there is no additional data to interpret the meaning
of this phenomenon. Mahapatro et al., [17] reported sim-
ilar distribution of mast cells in the metastatic lymph
nodes of breast cancer patients who survived or did not
survive 5-year. Bowers et al., reported high mast cell count
in the axillary lymph nodes of breast cancer patientsWorld Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/25
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surviving for 5 years compared to non-survivor [14].
However, Naik et al., stated that Bowers' results might be
due to no metastasis in survivors, or less number of meta-
static nodes compared to non-survivors [16]. Taken
together, it is possible that the patient's survival is not
related to the number of mast cells in lymph nodes, and
the role of mast cells in metastatic lymph nodes remains
unclear.
Two theories were considered while evaluating our
results: (i) metastasis occurs when cancer cells inhibit
mast cell functions either directly or indirectly by produc-
ing an inhibiting activator that works against mast cells,
resulting in a decrease in the number of mast cells as the
cancer spreads, and (ii) because mast cells cannot be
stained histologically when complete mast cell degranula-
tion occurs, a decrease in the number of mast cells
observed may be the result of degranulation rather than
exit. Based on this view, cancer cells may induce mast cell
degranulation, thereby resulting in some type of interac-
tion between mast cell degranulation products and cancer
cells. The exact relationship between mast cells and cancer
cells remains unclear. Further studies are required not
only to determine whether mast cells are for or against
tumor growth and metastasis, but also to establish that
the decreased observed is true decrease and not because of
inability to stain the mast cells due to its degranulation.
We hope to address this question in our next investigation
designed using monoclonal antibodies against mast cells.
The standard deviations of mast cell count of our results
are relatively large. There might be other factors influenc-
ing mast cell distribution, thereby resulting in the large
range of the standard deviation. For example, mast cell
counts in the sinuses of axillary nodes from breast cancer
patients had been reported to vary with the type of sinus
reaction present [18].
We noted an almost complete absence of mast cells in the
follicle of the "virgin" B cell area of lymph nodes and
observed a significant number of mast cells in the paracor-
tical or thymus dependent (T-cell) area. These results are
consistent with an earlier study of axillary lymph nodes
from breast cancer patients [17]. Furthermore, Burnet
speculated that mast cells and basophilic leukocytes or
some subpopulation of such cells are derivatives of thy-
mus-derived lymphocytes [19]. The predominance of
mast cells in the T-cell area in mediastinal lymph nodes in
our study also supports the theory that the origin of mast
cells is related to the T-cell system. McKinnon et al., sug-
gested that a large number of cytotoxic T-cells are activated
by tumor-draining reactive lymph nodes, thereby result-
ing in an increased secretion of interleukins and an expan-
sion of the mast cell population [20].
As reported previously, the number of mast cells stained
in formalin-fixed specimens is consistently less than in
specimens fixed in Carnoy's solution [21,22]. In the
Mediastinal lymph nodes showing abundance of mast cells in  the subcapsular and medullary sinus Figure 1
Mediastinal lymph nodes showing abundance of mast cells in 
the subcapsular and medullary sinus. (Alcian blue and safranin 
O staining. ×100)
Mast cell counts (mean ± SD) in mediastinal lymph nodes Figure 2
Mast cell counts (mean ± SD) in mediastinal lymph nodes. 
Group A vs. B: P = 0.0155; Group B vs. C: P = 0.0064; Group 
A vs. C: P = 0.0019 (Group A: metastasis negative, Group B: 
micro metastasis, Group C: metastasis positive)
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present study, we used formalin-fixed specimens because
we could not obtain specimens fixed in other solutions.
Therefore, the possibility remains that our results would
be different if our specimens had been preserved in Car-
noy's solution.
Conclusions
In our study, mast cells were seen primarily in T-cell areas,
thereby suggesting a positive relationship between mast
cells and the T-cell system. Although we observed an
inverse relation between the number of mast cells and the
amount of tumor tissue, the reasons for this remains
unclear. Further studies using enzyme specific staining
and CD antigens are required to determine exact relation-
ship of mast cells and cancer cells in the metastatic lymph
nodes.
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